# US 2012/0269820 A1 · Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269820 A1
- Document ID: US20120269820A1
- Status: Published application
- Kind: A1
- Application number: 13/492,280
- Filed: 2012-06-08
- Published: 2012-10-25
- Earliest claimed: 2008-05-05
- Assignees: NovImmune S.A.
- Inventors: Krzysztof Masternak; Olivier Leger
- Web page: https://patentgrep.com/patent/US20120269820A1

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.

## Claims

### Claim 1

An isolated antibody, or an antigen-binding fragment thereof, that (1) binds IL-17A homodimer, IL-17F homodimer and the IL-17A/IL-17F heterodimeric complex, wherein the antibody (2) exhibits (i) a binding affinity of at least 100 pM or less against the IL-17A homodimer, (ii) a binding affinity of at least 300 pM or less against the IL-17F homodimer, (iii) a binding affinity of at least 400 pM or less against the IL-17A/IL-17F heterodimeric complex, (iv) a neutralizing ability of at least 13 nM or less against the IL-17A homodimer, (v) a neutralizing ability of at least 120 nM or less against the IL-17F homodimer, and (vi) a neutralizing ability of at least 31 nM or less against the IL-17A/IL-17F heterodimeric complex, wherein the binding affinity is measured by surface plasmon resonance, and the neutralizing ability is determined by measuring IL-6 secretion by IL-17-stimulated mouse or human embryonic fibroblasts.

### Claim 2

An isolated antibody, or an antigen-binding fragment thereof, which comprises:
(a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 57, 60, 66, 69, 76, 79, 82, or 85;
(b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 58, 61, 63, 65, 67, 70, 72, 74, 77, 80, 83, 86, 93 or 94;
(c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 59, 62, 64, 68, 71, 73, 75, 78, 81, 84, 87, or 95;
(d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 96, 101, 104, 107 or 110;
(e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 97, 102, 105 or 108; and
(f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 98, 99, 100, 103, 106, 109, or 111,
wherein said antibody binds IL-17F and IL-17A.

### Claim 3 (depends on 2)

The antibody, or an antigen-binding fragment of claim 2, comprising (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 2, 6, 8, 10, 14, 18, 20, 24, 28, 32, 38, 52, or 54; (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 4, 12, 16, 22, 26, 30, 36, 40 or 56; or (c) a VH sequence as in (a) and a VL sequence as in (b), or an antigen-binding fragment thereof.

### Claim 4 (depends on 3)

The antibody or antigen-binding fragment of claim 3, comprising a VH sequence of SEQ ID NO: 2, 6, 8, 10, 14, 18, 20, 24, 28, 32, 38, 52, or 54

### Claim 5 (depends on 3)

The antibody of claim 3, comprising a VL sequence SEQ ID NO: 4, 12, 16, 22, 26, 30, 36, 40 or 56.

### Claim 6

An antibody comprising a VH sequence of SEQ ID NO: 2, 6, 8, 10, 14, 18, 20, 24, 28, 32, 38, 52, or 54, and a VL sequence SEQ ID NO: 4, 12, 16, 22, 26, 30, 36, 40 or 56, or an antigen-binding fragment thereof.

### Claim 7 (depends on 6)

The antibody or antigen-binding fragment of claim 6, which is monoclonal.

### Claim 8 (depends on 7)

The antibody or antigen-binding fragment of claim 7, which is human, humanized, or chimeric.

### Claim 9 (depends on 7)

The antibody or antigen-binding fragment of claim 7, which is an antibody fragment that binds IL-17F and IL-17A.

### Claim 10 (depends on 9)

The antibody, or antigen-binding fragment of claim 9, wherein said fragment is selected from the group consisting of Fab, Fab′, F(ab′)2, and Fv fragments; diabodies; and
single-chain antibody molecules.

### Claim 11 (depends on 7)

The antibody, or antigen-binding fragment of claim 7, which is an IgG isotype.

### Claim 12 (depends on 11)

The antibody, or antigen-binding fragment of claim 11, which is an IgG1 or IgG4 isotype.

### Claim 13 (depends on 2, 3, 4, 5, 6)

Isolated nucleic acid encoding the antibody of claims 2-6, or an antigen-binding fragment thereof.

### Claim 14 (depends on 13)

A host cell comprising the nucleic acid of claim 13.

### Claim 15 (depends on 14)

A method of producing an antibody, or antigen-binding fragment thereof, comprising culturing the host cell of claim 14 so that the antibody, or antigen-binding fragment thereof is produced.

### Claim 16 (depends on 1)

An immunoconjugate comprising the antibody, or antigen-binding fragment of claim 1, and a cytotoxic agent.

### Claim 17 (depends on 1, 16)

A pharmaceutical composition comprising the antibody, or antigen-binding fragment of claim 1, or an immunoconjugate of claim 16, and a carrier.

### Claim 18 (depends on 1)

The antibody, or antigen-binding fragment of claim 1 for use as a medicament.

### Claim 19 (depends on 1)

The antibody, or antigen-binding fragment of claim 1, for use in treating rheumatoid arthritis, psoriasis, multiple sclerosis, or inflammatory bowel disease.

### Claim 20 (depends on 1)

The antibody, or antigen-binding fragment of claim 1, for use in inhibiting IL-17A homodimer, IL-17F homodimer and IL-17A/F heterodimer mediating pro-inflammatory cytokine and/or chemokine production.

### Claim 21 (depends on 1)

Use of the antibody, or antigen-binding fragment of claim 1, in the manufacture of a medicament.

### Claim 22 (depends on 1)

A method of treating an individual having rheumatoid arthritis, Crohn's disease, psoriasis, multiple sclerosis, chronic obstructing pulmonary disease, or asthma, comprising administering to the individual an effective amount of the antibody, or antigen-binding fragment of claim 1.

### Claim 23 (depends on 22)

The method of claim 22, wherein said subject is a human.

### Claim 24 (depends on 1)

A method of treating an individual having an autoimmune disease, inflammatory disorder or cell proliferation disorder, comprising administering to the individual an effective amount of the antibody, or antigen-binding fragment of claim 1.

### Claim 25 (depends on 24)

The method of claim 24, wherein said subject is a human.
